SCHEMBL880496

SCHEMBL880496

O=C1CC(c2cc(Cl)ccc2Cl)c2ccc3ccccc3c2N1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.61
ALDH1A1 P00352 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
KMT2A Q03164 1/20 0.61
HSD17B10 Q99714 1/20 0.58
MAPT P10636 4/20 0.56
HTT P42858 1/20 0.56
TP53 P04637 6/20 0.53
MAPK1 P28482 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
IDO1 P14902 5/20 0.49
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880224 0.93 TP53 (0.62) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880297 0.88 LMNA (0.64) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL14942738 0.88 LMNA (0.59) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880435 0.85 MAPT (0.68) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880430 0.85 LMNA (0.67) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880302 0.84 LMNA (0.65) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL14450608 0.84 LMNA (0.61) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880437 0.84 LMNA (0.61) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880307 0.83 IDO1 (0.70) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880438 0.82 LMNA (0.74) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT LMNA 525/4885ALDH1A1 171/4885SMN1; SMN2 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.